ddodell@stjhmc.fidonet.org (David Dodell) (08/30/90)
Current Drugs being tested for AIDS related use
Non-commercial reproduction approved
8/90
DRUG MANUFACTOR TARGET STUDY TYPE DATE
==============================================================================
=
566C80 Burroughs Wellcome PCP treatment Phase I AI 2/90
Rsch. Triangle Pk, NC
AS-101 Wyeth-Ayerst Labs AIDS, ARC Phase I/II IM 2/90
Philadelphia
AS-101 Wyeth-Ayerst Labs AIDS, ARC Phase I/II IM 2/90
w/ Retrovir Philadelphia
(AZT)
AzdU Triton Biosciences AIDS, ARC Phase I AV 11/89
(Azidouridine) Alameda CA
Bactrim* Hoffmann-La Roche PCP treatment APPROVED Summer 89
Trimethoprim Nutley NJ
and
Sulfamethoxazole
Betaseron* Triton Biosciences ARC, KS, AIDS Phase II C 2/90
Recombinant Alameda CA
Human Inter-
feron Beta
Betaseron* Triton Biosciences ARC, AIDS Phase I C 2/90
(Recombinant Alameda CA
Human Inter-
feron Beta)
with Retrovir*
(AZT)
Bropirimine Upjohn KS Phase II IM 11/89
(ABPP) Kalamazoo MI
Butyl DNJ G. D. Searle AIDS, ARC Phase I AV 11/89
Deoxynojirmycin Chicago IL
CD4-IgG Genentech ARC, AIDS Phase I AV 11/89
CD4 Immuno- S. San Francisco CA
adhesin
AISummer 89
Cilofungin Eli Lilly & Co. candida IND APPROVED
Indianapolis IN esophagitis
Clindamycin Upjohn PCP Treatment Phase I/II AI Summer
89
with Kalamazoo MI
Primaquine
Compound Q Genelabs, Inc. HIV infection, Phase I AV 11/89
GLQ 223 Redwood City CA ARC, AIDS
Cytovene* Syntex CMV retinitis Approved 2/90
(Ganciclovir Palo Alto CA
IV)
Cytovene* Syntex CMV retinitis Phase I/II AV 2/90
Ganciclovir Palo Alto CA
(oral)
Cytovene* Syntex CMV retinitis Phase III AV 2/90
(Ganciclovir Palo Alto CA
IV)
w/ Betaseron
(Recombinant
Human Interferon
Beta)
d4T Bristol-Myers AIDS, ARC Phase I/II AV 11/89
Squibb
(Didehydrode- New York NY
oxythymidine)
Dapsone Jacobus PCP prophylaxis Phase II/III AI 2/90
w/NebuPent Pharmaceuticals
(Aerosol Princeton NJ
Pentamidine
Isethionate)
Dapsone with Jacobus PCP prophylaxis Phase III AI 2/90
Retrovir Pharmaceuticals
(AZT) Princeton NJ
Daraprim* Burroughs Wellcome toxoplasmosis APPROVED Summer 89
Pyrimethamine Rsch Triangle Park NC treatment
Daraprim* Burroughs Wellcome toxoplasmosis Phase II AI 2/90
Pyrimethamine Rsch Triangle Park NC prophylaxis
ddC Hoffman-La Roche AIDS, ARC, Phase I/II AV 2/90
(Dideoxycyti- Nutley NJ
dine)
ddC Hoffman-La Roche AIDS, ARC, Phase II/III AV 11/89
(Dideoxycyti- Nutley NJ (Orphan Drug)
dine)
with Retrovir (AZT)
------------------------------
pediatric HIV Phase I
(NCI Trial)
Diclazuril Janssen cryptosporidiosis Phase I AI Summer 89
Pharmaceutica
Piscataway NJ
Diflucan Pfizer cryptococcal APPROVED 2/90
(Fluconazole) New York NY meningitis,
candidiasis
EL10 Elan Corp. PLC HIV infection Phase I/II IM 2/90
DHEA Gainesville GA
EPREX* Ortho Pharmaceutical severe anemia C 11/89
Treatment
IND
(Recombinant Human Raritan NJ associated
Erythropoietin) w/AIDS and
Retrovir therapy
FIAC Oclassen CMV infection Phase I/II AI 2/90
Fiacitibine Pharmaceutical
San Rafael CA
Gamiune-N* Cutter Biological pediatric HIV Phase II/III IM
Summer 89
Human Serum Berkeley CA infection
Globulin
Gamiune-N* Cutter Biological ARC, AIDS Phase II/III IM
Summer 89
Human Serum Berkeley CA
Globulin
w/Retrovir (AZT)
Granulocyte Immunex KS Phase I/II CSF 2/90
(GMC-SF)
with Roferon*-A
(Interferon alfa-2a)
and Retrovir* (AZT)
Granulocyte Sandoz leukopenia Phase II/III CSF 2/90
E. Hanover NJ associated
with HIV
infection
(GMC-SF) Genetics Institute
Cambridge MA
Schering-Plough
Madison NJ
Granulocyte Sandoz CMV retinitis Phase II/III CSF 2/90
E. Hanover NJ
(GMC-SF) with
Cytovene* Genetics Institute
(Ganciclovi Cambridge MA
Schering-Plough
Madison NJ
Granulocyte Sandoz AIDS Phase II/III CSF 2/90
Macrophage/ E. Hanover NJ
(GMC-SF) with
Retrovir* Genetics Institute
(AZT) Cambridge MA
Schering-Plough
Madison NJ
HIVAC-Ie Bristol-Myers Squibb/ HIV negative, Phase I V 11/89
Oncogen early HIV
New York NY infection
IL-2 Hoffman-La HIV, ARC, AIDS, Phase I CSF 11/89
(Interleukin-2)Roche in combination
Nutley NJ w/ Retrovir
Immunex
Seattle WA
Imuthiol Merieux Institute ARC, AIDS; Phase III IM 11/89
(Diethyl- completed
dithio- Miami FL ----------------------------
carbamate ARC, AIDS, in Phase III
or DTC) combination w/ completed
Retrovir
Intron A* Schering-Plough KS APPROVED 11/89
Interferon alpha Madison NJ
2b
------------------------------------------------------------------
AIDS, in com- Phase II
bination w/
Retrovir
Iscador Hiscia HIV infection, Phase I/II AV 2/90
Switzerland ARC,AIDS
Lentinan Lenti-Chemico HIV+ Phase I/II IM 11/89
b-(1-3)glucan Pharmaceuticals asymptomatic and
Teaneck NJ symptomatic, ARC,
AIDS, pediatric
AIDS
Megace* Bristol-Myers Squibb treatment of Phase II/III O 11/89
(Megestrol New York NY anorexia and
Acetate) cachexia
associated with
AIDS
Mesalamine Norwich Eaton inflammatory Phase I/II O 2/90
Norwich NY bowel syndrome
associated with
HIV infection,
ARC, AIDS
Mycostatin* Bristol-Myers prevention of oral Phase III AV 2/90
Pastille Squibb candidiasis
(Nystatin Princeton NJ
Pastille)
NebuPent* LyphoMed PCP prophylaxis APPROVED 11/89
Aerosol Rosemont IL (Orphan Drug)
Pentamidine
Isethionate
-------------------------------------
PCP treatment Phase III
(Orphan Drug)
Neupogen* Amgen AIDS, ARC, in combination Phase I CSF 11/89
(Granulocyte) Thousand Oaks w/Retrovir
CA
Nizoral* Janssen Pharmaceutica candida Phase III AI 11/89
Ketoconazole Piscataway NJ esophagitis
(suspension)
Ornidyl Merrell Dow PCP IND APPROVED AI Summer 89
(Eflornithine)Cincinnati OH (orphan drug)
Pentam* 300 LyphoMed PCP treatment APPROVED Summer 89
IM & IV Rosemont IL
Pentamidine
Isethionate
Peptide T Peninsula Labs AIDS, ARC Phase I AV Summer 89
d-ala-peptide T Belmont CA
Piritrexim Burroughs Wellcome PCP treatment Phase I/II AI Summer 89
Research Triangle
Park, NC
Pneumopent* Fisons Corporation PCP prophylaxis Phase III AI 11/89
(Aerosol Bedford MA
Pentamidine
Isethionate)
rCD4 Genentech ARC, AIDS, in Phase I/II AV 11/89
(Recombinant S. San Francisco CA combination (Orphan Drug)
Soluble w/ Retrovir
Human CD4)
---------------------------------
pediatric HIV Phase I
infection
Receptin* Biogen AIDS, ARC Phase I AV Summer 89
(Recombinant Cambridge MA
Soluble
Human CD4)
Retrovir* Burroughs Wellcome AIDS, adv, ARC NDA 11/89
APPROVED
(Zidovudine; Research Triangle
AZT) Park, NC
----------------------------------
pediatric AIDS, KS, Phase I/II
asymptomatic HIV
infection, early HIV
disease, neurological
involvement in combi-
nation w/other therapies,
post-exposure prophyl-
axis in health care
workers, neonatal AIDS
Ribafutin Adira Labs MAI prophylaxis Phase III AI 2/90
Columbus OH
Roferon-A* Hoffmann-La Roche KS Approved 11/89
(Interferon Nutley NJ
alpha-2a)
Roferon-A* Hoffmann-La Roche ARC, AIDS Phase II C 2/90
(Interferon Nutley NJ (NIAID
alpha-2a) trials)
with Retrovir
(AZT)
Salk HIV I early HIV infection Phase II/III V 2/90
Immunogen* Products
Horsham PA
Sandostatin* Sandoz HIV-related diarrhea Phase II/III O 2/90
Somatostatin E Hanover NJ
Septra* Burroughs Wellcome PCP treatment APPROVED Summer 89
Trimethoprim Rsch. Triangle Pk NC
and
Sulphamethoxazole
SK&F106528 SmithKline HIV+ asymptomatic Phase I/II AV 2/90
Recombinant Beckman and symptomatic,
Soluble T4 Philadelphia PA ARC
Spiramycin Rhone-Poulenc cryptosporidial Phase II/III AI
Summer 89
Pharmaceuticals diarrhea
Princeton NJ
Sporanox* Janssen Pharmaceutica maintenance for Phase III AI 2/90
(Intraconazole- Piscataway NJ cryptococcal
R51211) meningitis,
histoplasmosis
Thymic Humoral Adria Laboratories HIV positive Phase I IM Summer 89
Factor Dublin OH
TI-23 Teijin Ltd. CMV infection Phase I AI Summer 89
CMV Monoclonal Tokyo Japan
Timunox* Immunobiology HIV infection Phase II C 11/89
(Thymopentin Research Institute
or TP/5) Clinton NJ
Trimetrexate Warner-Lambert PCP Treatment IND; AI 11/89
with Morris Plains NJ Phase III
Leukovorin
Uendex* Ueno FCI Ltd. AIDS, ARC, HIV+ Phase I/II AV Summer
89
Dextran Sulphate Osaka, Japan asymptomatic
------------------------------
HIV infection Phase I
VaxSyn* MicroGeneSys HIV- Phase I/II as vaccine V 2/90
HIV-1 West Haven CT
-------------------------------
(gp160) early HIV Phase I as therapeutic
infection
VIDEX* Bristol-Myers Squibb AIDS, ARC AV 2/90
Treatment
IND;
(ddI or dideo- New York NY Phase II/III
oxyinosine)
-----------------------------
pediatric Phase I/II
HIV infection
Wellferon Burroughs Wellcome KS, HIV Phase I/II C 2/90
(Alpha Research Triangle
Interferon) Park, NC
with Retrovir*
(AZT)
Zovirax Burroughs Wellcome CMV retinitis, Phase II/III AV 2/90
(Acyclovir) Research Triangle herpes zoster
Park, NC
Zovirax Burroughs Wellcome CMV retinitis, Phase II/III AV 2/90
(Acyclovir) Research Triangle herpes zoster
with Retrovir* Park, NC
(AZT)
------------
* Registered Trademark
Legend:
IM - Immuno-modulator
AI - Anti-infective
CSF - Colony Stimulant Factor
O - Other
I - Immunization
AV - Anti-viral
V - Vaccine
C - Cytokine
--
-------------------------------------------------------------------------
St. Joseph's Hospital and Medical Center, Phoenix, Arizona
uucp: {gatech, ames, rutgers}!ncar!asuvax!stjhmc!ddodell
Bitnet: ATW1H @ ASUACAD FidoNet=> 1:114/15
Internet: ddodell@stjhmc.fidonet.org FAX: +1 (602) 451-1165